Rabeprazole-13C,d3

Rabeprazole-13C,d3

• CAS Number: 1261392-48-6
• UNSPSC Description: Rabeprazole-13C,d3 is a deuterated labeled Rabeprazole[1]. Rabeprazole (LY307640) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole induces apoptosis. Rabeprazole acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 of 0.3 μM. Rabeprazole can be used for the research of gastric ulcerations and gastroesophageal reflux[2][3][4].
• Target Antigen: Apoptosis; Bacterial; Isotope-Labeled Compounds; Proton Pump
• Type: Isotope-Labeled Compounds
• Related Pathways: Anti-infection;Apoptosis;Membrane Transporter/Ion Channel;Others
• Field of Research: Cancer
• Smiles: CC(C(OCCCO[13C]([2H])([2H])[2H])=CC=N1)=C1CS(C2=NC3=CC=CC=C3N2)=O
• Molecular Weight: 363.45
• References & Citations: [1]Tara A Shea, et al. Identification of Proton-Pump Inhibitor Drugs That Inhibit Trichomonas Vaginalis Uridine Nucleoside Ribohydrolase. Bioorg Med Chem Lett. 2014 Feb 15;24(4):1080-4.|[2]Aly A M Shaalan, et al. Supplement With Calcium or Alendronate Suppresses Osteopenia Due to Long Term Rabeprazole Treatment in Female Mice: Influence on Bone TRAP and Osteopontin Levels. Front Pharmacol. 2020 May 13;11:583.|[3]Mengli Gu, et al. Rabeprazole Exhibits Antiproliferative Effects on Human Gastric Cancer Cell Lines. Oncol Lett. 2014 Oct;8(4):1739-1744.|[4]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported